About US
Contact us
Position：Home > Phexcom News >
-
Express Scripts: AbbVie hep C meds still available for the right patientsA newFDAwarning about AbbVie's ($ABBV) hepatitis C cocktail hasn't affected patients' access to treatment, pharmacy benefits manager Express Scripts ($ESRX) said on Wednesday. Viekira Pakis still ava2015/10/29
-
GSK chief: We don't need a breakup or a Pfizer deal. Just look at ViiV's sales surgeGlaxoSmithKline ($GSK) surpassed Wall Street's earnings estimates in Q3, with lower spending in vaccines and consumer health largely driving the beat. But that's not to say it didn't turn in a couple2015/10/29
-
Pfizer gives up on a pair of Xeljanz indications--and it may dump psoriasis, tooA host of next-gen psoriasis competitors are getting ready to break onto the scene, which means there's not much room for Pfizer's ($PFE)Xeljanz--and the company knows it. Pfizer says it'll "reconside2015/10/29
-
Bristol-Myers rides Opdivo, hep C sales to Q3 beatBristol-Myers Squibb ($BMY) expects big things from its immunotherapy powerhouseOpdivo, pushing for expanded indications for the med as it competes for the top spot in the field. Now the company is ce2015/10/28
-
Merck's Remicade bleeds market share to biosims, but Januvia holds its ownAlong with its third-quarter financials, Merck & Co. ($MRK) delivered some more bad news about itsRemicadebrand: Discounted biosimilar versions are grabbing market share and eroding sales, and tha2015/10/28
-
Pfizer blows past sales forecasts, thanks to overachievers Prevnar, IbranceLast quarter, vaccine giantPrevnar 13and breast-cancer newcomerIbranceoutperformed expectations, helping Pfizer ($PFE) trump analyst estimates. And in Q3, they delivered repeat performances. The phar2015/10/28
-
Kadcyla's miss in stomach cancer dents Roche's effort to reap more from new drugsRoche ($RHHBY) is pinning its hopes on cancer powerhouseKadcyla, priming the drug for new indications as it looks to soften the blow once biosimilars for top-selling meds come knocking. But now the co2015/10/26
-
PhRMA throws controversy-ridden Valeant under the busPharma industry trade groupPhRMAgenerally protects its own amid controversy. But now, it's put up a statement on its website criticizing a drugmaker that's surrounded by plenty. On Thursday, the grou2015/10/26
-
Witty insists GSK's safe approach, backed by innovative pipeline, is the way to successGlaxoSmithKline CEOAndrew Wittycontinues to take heat for moving the U.K. drugmaker heavier into low-margin areas like consumer health and vaccines. But he continues to insist he has it on the right t2015/10/26
-
CFDA Minister Bi Jingquan meets CEO of the Bill & Melinda Gates FoundationOn the morning of October 22, 2015, Bi Jingquan, Minister of China Food and Drug Administration (CFDA), met with the delegation led by Dr. Sue Desmond-Hellmann, the Chief Executive Officer of the Bill2015/10/26